Stay updated on SAGE-217 in Essential Tremor Clinical Trial

Sign up to get notified when there's something new on the SAGE-217 in Essential Tremor Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SAGE-217 in Essential Tremor Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:03:18.000Z thumbnail image
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the evaluation of SAGE-217 in adult participants with essential tremor. The change possibly reflects new information on the efficacy, safety, tolerability, or pharmacokinetics of the drug in the study.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:33.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that participants must have a diagnosis of Essential Tremor (ET) with certain characteristics. Previously, no information was provided under Participation Criteria Collaborators and Investigators.
    Difference
    18%
    Check dated 2024-05-22T21:15:11.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:42.000Z thumbnail image

Stay in the know with updates to SAGE-217 in Essential Tremor Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SAGE-217 in Essential Tremor Clinical Trial page.